MicroRNA-181a* Targets Nanog in a Subpopulation of CD34(+) Cells Isolated From Peripheral Blood. by Mintz, Paul J et al.
UCSF
UC San Francisco Previously Published Works
Title
MicroRNA-181a* Targets Nanog in a Subpopulation of CD34(+) Cells Isolated From 
Peripheral Blood.
Permalink
https://escholarship.org/uc/item/42j6j6kc
Journal
Molecular therapy. Nucleic acids, 1(8)
ISSN
2162-2531
Authors
Mintz, Paul J
Sætrom, Pål
Reebye, Vikash
et al.
Publication Date
2012
DOI
10.1038/mtna.2012.29
 
Peer reviewed
eScholarship.org Powered by the California Digital Library
University of California
Citation: Molecular Therapy–Nucleic Acids (2012) 1, e34; doi:10.1038/mtna.2012.29
© 2012 American Society of Gene & Cell Therapy All rights reserved 2158-3188/11
www.nature.com/mtna
1Department of Surgery and Cancer, Faculty of Medicine, Imperial College London, London, UK; 2Department of Cancer Research and Molecular Medicine, Norwegian 
University of Science and Technology, Trondheim, Norway; 3Department of Computer and Information Science, Norwegian University of Science and Technology, 
Trondheim, Norway; 4Genetic Systems, Applied Biosystems, Part of Life Technologies, Foster City, California, USA;  5Division of Molecular Biology, Beckman Research 
Institute of City of Hope, Duarte, California, USA; 6Department of Medicine, University of California, San Francisco, California, USA; 7Department of Medicine, UCLA 
School of Medicine, Los Angeles, California, USA;  8Qatar Biomedical Research Institute, Education City, Doha, Qatar; 9Department of Virology, School of Veterinary 
Medicine, Cairo University, Cairo, Egypt; 10Department of Hematology, Faculty of Medicine, Imperial College London, London, UK. Correspondence: Nagy A Habib, 
Department of Surgery and Cancer, Faculty of Medicine, Imperial College London, London, UK. E-mail: nagy.habib@imperial.ac.uk (or) Paul J Mintz, Department of 
Surgery and Cancer, Faculty of Medicine, Imperial College London, London. E-mail: p.mintz@imperial.ac.uk
Keywords: CD34+; Nanog; miR-181a*; stem cells
Received 10 May 2012; revised 27 June 2012; accepted 27 June 2012
INTRODUCTION
In recent years, studies in embryonic and somatic stem cells 
have provided basic insight into the molecular and cellular 
properties of stem cells.1 It is recognized that pluripotent stem 
cells such as embryonic stem cells (ESC) can replenish dif-
ferentiated cell types and achieve long-term tissue reconsti-
tution. Similar to ESC, adult stem cells also have the capacity 
for self-renewal and multilineage differentiation.2 Adult stem 
cells constitute ~1–2% of the total cell population within a 
specific tissue and are essential for maintaining homeostasis. 
These cells are normally quiescent and are held in an undif-
ferentiated state within their niche until they receive a signal 
to self-renew or differentiate.3 They reside in various tissue 
types including the bone marrow, brain, digestive system, 
skin, retina, muscles, pancreas, and liver.4
Hematopoietic stem cells (HSC) are the most widely 
studied and characterized adult stem cells.5 They play an 
essential role in sustaining the formation of the blood and 
the immune system.6,7 These adult stem cells reside in the 
bone marrow along with mesenchymal stem cells (MSC).5,8 
It was previously thought that adult stem cells were lineage 
restricted; however, recent studies have shown that HSC and 
mesenchymal stem cells have enormous plasticity.9,10 These 
characteristics have made them attractive for developing 
stem cell-based therapies. Moreover, they offer several 
advantages including ease of manipulation, lack of serious 
ethical issues and, in the autologous setting, the absence of 
immunogenicity.
MicroRNAs (miRNAs) are short single-stranded RNA mol-
ecules of about 17–25 nucleotides that control gene expres-
sion post-transcriptionally in many different cellular processes 
either by blocking translation or by inducing mRNA degra-
dation through sequence complementation.11–14 Although 
numerous signaling pathways, transcription factors and epi-
genetic changes are essential cellular regulators in determin-
ing stem cell fate, recent studies have shown that miRNAs 
are also implicated in coordinating the necessary changes 
in gene expression.15 Typically, miRNAs are capable of con-
trolling the fate of cells in a time and tissue specific manner 
through regulation of cellular differentiation, developmental 
patterning, and morphogenesis. Therefore, manipulation of 
miRNAs could potentially be a useful approach to developing 
strategies for stem cell therapy.
In this study, we investigated the role of miRNAs in an adher-
ent subpopulation of CD34+ cells isolated from granulocyte 
colony-stimulating factor mobilized peripheral blood cells. We 
identified several clusters of miRNAs that were differentially 
expressed in these stem cells by miRNA profiling. Further 
analysis of one of the clusters revealed a miRNA that targets 
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the stem cell gene Nanog. We show specifically that miR-181a* 
targets the 3′UTR of Nanog. Our data provide evidence that 
miR-181a* targets Nanog in a subpopulation of CD34+ cells.
RESULTS
miRNA expression in CD34+ progenitor cells
We performed miRNA profiling on a subpopulation of adher-
ent CD34+ cells mobilized peripheral blood cells.16 Using a 466 
miRNA chip, we compared the miRNA signatures of adher-
ent and nonadherent CD34+ cells (Figure 1a). These two sub-
populations of CD34+ cells have previously been established 
as having distinct morphology, immunophenotype, and gene 
expression profile.16 Moreover, the adherent CD34+ cells dis-
play greater plasticity than the nonadherent population as they 
have the potential to express determinants specific to liver, 
pancreas, heart, muscle, and nerve cell differentiation.16 Hier-
archical clustering revealed eight unique miRNA clusters that 
were differentially expressed in the adherent and nonadher-
ent populations. This finding is not entirely surprising since the 
biological roles of miRNAs are known to vary according to their 
expression in distinct cell populations in normal tissues.17,18 
Interestingly, there were several miRNAs that have not been 
previously characterized for human in cluster 8 (Table 1). We 
were particularly interested in the miRNAs in cluster 8 because 
among the miRNAs in this cluster, miR-181a* (miR-181a-3p) 
was highly upregulated and studies have also shown that the 
miR-181 family are associated with regulation of CD34+ cells. 
However, the mRNA targets are largely unknown.18,19 We did 
identify some conserved regions within the mature human 
miR-181 family of sequences which consist of miR-181a, miR-
181b, miR-181c, and miR-181d (Figure 1b). We have taken 
the first step toward better understanding the role of miR-
181a* in CD34+ cells.
We first determined whether miR-181a* affected the alka-
line phosphatase activity in these cells. Higher alkaline phos-
phatase activity is generally associated with stem cells that 
are in a less differentiated state.20 We found increasing lev-
els of alkaline phosphatase activity in cells transfected with 
miR-181a* inhibitor when compared to transfection with miR-
181a* mimic (Figure 1c). The data raises the possibility that 
these stem cell population could be maintained in a less dif-
ferentiated state by inhibiting miR-181a* expression.
Figure 1 MicroRNA profile of CD34+ stem cells. (a) Unsupervised hierarchical clustering heat map of microRNA (miRNA) expression 
using expression levels (Ct value) of 192 miRNAs, P < 10–5. Higher Ct values correspond to a lower expression level (red color on the 
heat map). Eight distinct miRNA clusters were identified. (b) A multiple sequence alignment of human miR-181 family by ClustalW. The 
 miR-181a* is the same as miR-181a-3p. (c) Alkaline phosphatase activity was performed 72 hours post-transfection. Bar represents mean 
± SD (n = 3). Student’s t-test, * P < 0.01.
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miRNA-181a* targets Nanog 3′UTR
We next applied an in-house genomic-bioinformatics data-
base to identify and validate potential candidate target mes-
sages for miR-181a*. Being important factors in stem cell 
maintenance, the genomic loci of Nanog, STAT3, Hic1, Sox2, 
HoxB4, and Pou5f1 (Oct4) were scanned for putative target 
sites that was complementary to the miR-181a* sequence 
(5′-accaucgaccguugauuguacc-3′). Specifically, the anno-
tated 3′ UTR sequences of these genes were scanned for 
seed sites with perfect reverse-complementarity to miRNA-
181a* seed sequence (nucleotides 2–7 from the 5′ end) and 
sites with strong overall complementarity to miRNA-181a*. 
Of the putative target genes, we discovered that miR-181a* 
formed the most stable base pairing at the Nanog 3′UTR 
(Figure 2a). Since Nanog is an important regulator of stem 
cell maintenance and self-renewal,21 we determined whether 
miR-181a* targeted Nanog transcripts. Using endpoint reverse 
transcription-PCR (RT-PCR) (Figure 2b) and quantitative 
RT-PCR (Figure 2c) in transfected CD34+ stem cells, we found 
that inhibiting miR-181a* significantly upregulates transcript 
levels of Nanog. It has been reported that there exists a sen-
sitive feedback loop that maintains the differentiation of stem 
cells through the control of essential stem cell genes such as 
Nanog. This loop enables where by environmental or molecu-
lar cues to influence the expression levels of genes, leading to 
a binary decision to switch downstream differentiation genes 
on or off.22 The data raises the possibility that miR-181a* may 
be involved in directly regulating Nanog expression in CD34+ 
stem cells.
Target validation of miR-181a* to the Nanog 3′UTR 
via 3′-compensatory site
To gain more insight into the functional interaction between 
miR-181a* and Nanog mRNA, we further interrogated the 
entire sequence alignment between the two RNA molecules. 
We discovered a high degree of base pairing at the 3′ region 
(7 nucleotides) and a weak base pairing at the 5′ seed site 
of miR-181a* (Figure 3a, top panel). In general most miRNA 
target sites have a strong base pairing at the 5′ seed site 
(7–8 nucleotides).11 However, the 5′ seed site rule is not 
always the case and studies have shown that the 3′ region 
of miRNA also play an important role in targeting mRNA but 
are rare events.11 These sites at the 3′ region of miRNAs are 
called 3′-supplementary and 3′-compensatory sites.11,23,24 In 
addition to the 3′ sites, a recent report has identified another 
site called the centre site25 suggesting that miRNA targeting 
is more complex and diverse. In our case, because the base 
pairing at the 5′ seed site of miR-181a* was weak, we specu-
lated that the strong complementarity pairing at the 3′ region 
would compensate and may follow the 3′-compensatory site 
rule similar to one of the earlier miRNA that was discovered 
such as let-711,26 (Figure 3a, bottom panel). Both miR-181a* 
and let-7 miRNAs, in this setting show a very similar over-
all structural identity in the way they bind to their targets. To 
determine whether the 3′ region of miR-181a* was impor-
tant, we generated, using RNAhybrid modeling,26,27 the most 
energy stable complementarity base pairing between miR-
181a* and Nanog 3′ UTR mRNA (Figure 3b, top panel) as 
well as determining the best mutations that would disrupt the 
3′ region base pairing. This was generated by replacing two 
bases at the 3′UTR of Nanog (Figure 3b, bottom panel).
To test this modeling we generated a dual-luciferase 
reporter construct for miR-181a* and Nanog 3′ UTR mRNA. 
We inserted, upstream of the firefly luciferase gene, either the 
wild-type 3′UTR of Nanog or a mutant variant containing the 
two point mutations predicted to abolish miR-181a* targeting 
(Figure 3b, bottom panel). Transfecting the wild-type Nanog 
3′UTR reporter construct by itself or with the miR-181a* 
mimic into CD34+ stem cells significantly reduced expres-
sion of luciferase (Figure 3c). Transfecting miR-181a* inhibi-
tor caused a significant reversal in suppression of luciferase 
expression indicating that binding of miR-181a* to the 3′UTR 
of Nanog was suppressed thus allowing expression of the 
luciferase reporter. By contrast, transfection of the mutant 
Nanog 3′UTR reporter alone or in combination with miR-181a* 
mimic or inhibitor had no repressive effect on expression of the 
luciferase reporter (Figure 3c). This data therefore suggests 
that miR-181a* directly targets the 3′UTR region of Nanog. 
Table 1 miRNAs from cluster 8 targets and functions in human stem cells
miRNA
Putative 
target(s) Known function(s) Refs.
miR-191 SOX4 Helps the transition of epithelial 
cells into mesenchymal cells
41
miR-30c PAI-1, ALK2 Enhances the differentiation of 
osteocytes and adipocytes; Controls 
mesenchymal and hematopoietic 
cell lineages progression
42,43
miR-150 NOTCH3 Mediates T-cell development 44
miR-17-5p E2F1, Bim Regulates stem cell differentiation 
and mediates embryonic 
development
45,46
miR-29a CDC24, 
TPM1, FZD5
Plays an important role in stem 
cell differentiation; Regulates early 
heamatopoiesis
47,48
miR-135b IBSP, Osterix Modulates osteoblastic 
differentiation.
49
miR-196a HOXC8 Plays a vital role in differentiation 
and proliferation of human adipose 
tissue-derived mesenchymal stem 
cells
50
miR-199a Aggrecan, 
SOX9, 
FABP4 
Regulates pluripotent stem cells 
(iPSCs) production; Mediates 
hMSC as well as chondrocyte 
differentiation
51,52
miR-148b Unknown Differentiation of hMSC 53
miR-374 Unknown Plays a role in neuronal progenitors 
transdifferentiated
54
miR-520c Unknown Hepatocyte differentiation 55
miR-133a Unknown Unknown
miR-483 Unknown Unknown
miR-411 Unknown Unknown
miR-381 Unknown Unknown
miR-515-
5p
Unknown Unknown
miR-107 Unknown Unknown
miR-187 Unknown Unknown
miR-296 Unknown Unknown
miR-135a Unknown Unknown
miR-181a* Unknown Unknown
Abbreviations: hMSC, human mesenchymal stem cells; miRNA, microRNA.
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This is the first attempt to characterize miR-181a* in CD34+ 
cells and we have identified Nanog as its potential target. 
DISCUSSION
Understanding the cellular and molecular mechanisms respon-
sible for the multi-pluripotency of stem cells will be critical for 
their practical use in therapy. MicroRNAs have been shown 
to be important and necessary for proper stem cell regula-
tion.18,28–30 In this study, we generated a miRNA profile from a 
subpopulation of adherent CD34+ cells isolated from G- colony-
stimulating factor mobilized peripheral blood and demonstrated 
a marked difference in expression patterns for a small clus-
ter of miRNA. Using bioinformatics, we identified Nanog as a 
potential target for miR-181a*. Interestingly, there have been 
works published regarding other potential targets for the miR-
181 family. For example, miR-181b has been shown to be an 
important regulator of nuclear factor-κB signaling in the vascu-
lar endothelium by targeting importin-α3.31 In another cell type, 
miR-181b has been shown to target Tcl1 oncogene in chronic 
lymphocytic leukemia.32 Similar to miR-181b, miR-181a also 
has several targets such as Prox1 in lymphatic endothelial 
cells, C2H2 zinc-finger proteins, and multiple phosphatases 
such as SHP2, PTPN22, DUSP5, and DUSP6.33–36 
Although miR-181a*′s binding site within the 3′UTR of 
Nanog displayed a weak canonical 5′ miRNA seed pairing, it 
also showed strong complementarity at the miRNA 3′ end and 
at the central Ago2 catalytic site 10–11 nucleotides from the 5′ 
miRNA site.27 This binding pattern is similar with the “3′ com-
pensatory site model previously identified with let7-miRNA.”11,23 
Importantly, by introducing two point mutations to disrupt the 3′ 
and central complementary sites, we abolished miR-181a* reg-
ulation of a reporter construct containing the 3′UTR of Nanog. 
Our studies highlight a new stem cell-related target for the miR-
181 family and show that miR-181a* directly targets Nanog.
MATERIALS AND METHODS
Isolation and growth of a CD34+ stem cell population. The 
hematopoietic blood samples were obtained with informed 
patient consent and approved by the Hammersmith Hospital 
Research Ethics Committee. Samples of granulocyte-colony 
stimulating factor mobilized peripheral blood progenitor cells 
were processed by leukapheresis at the Stem Cell Laboratory 
at the Hammersmith Hospital. Briefly, human mobilized periph-
eral blood samples were diluted in a ratio of 1:4 in Hanks’-
buffered saline solution (Gibco, Paisley, UK), the mononuclear 
cells were separated by centrifugation over a Lymphoprep 
(Dundee, Scotland) density gradient at 1,800 rpm for 30 min-
utes. The mononuclear cell fraction at the interface was aspi-
rated and washed twice with Hanks’-buffered saline solution, 
and finally with MACS buffer (phosphate-buffered saline solu-
tion) at pH 7.2 supplemented with 0.5% bovine serum albumin 
and 2 mmol/l EDTA). CD34+ cells were isolated using a CD34+ 
Figure 2  Identification of miR-181a* target gene. (a) Nanog genomic locus (hg18) and complementarity-binding site for miR-181a*. (b) 
mRNA expression level of Nanog by endpoint reverse transcription-PCR (RT-PCR) analysis. The panel shows quantified gel band intensity. 
Statistical analysis, *P < 0.001. (c) mRNA expression level of Nanog by quantitative RT-PCR normalized with GAPDH and calibrated with 
expression profile of Nanog in differentiated fibroblasts. Bar represents mean ± SD (n = 4). Statistical analysis, *P < 0.0005.
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isolation kit (Miltenyi Biotec, Cologne, Germany) according to 
the manufacturer’s protocol. Adherent CD34+ progenitor cells 
were isolated as previously described with modification.16 
Briefly, isolated CD34+ cells were added to 24-well or 35-mm 
tissue-culture treated dishes (Nunc, Roskilde, Denmark) at a 
density of 2.5–5 × 105 cells in α-minimum essential medium 
to isolate the adherent CD34+ cell population. After 30-min-
ute incubation, nonadherent cells were removed and adherent 
cells were rinsed three times with phosphate-buffered saline or 
α-minimum essential medium. The adherent CD34+ cell popu-
lation was grown in a serum-free medium (CellGro; CellGenix, 
Freiburg, Germany) containing three cytokines: 250 ng/ml of 
stem cell factor, 250 ng/ml of interleukin-6, and 250 ng/ml of 
interleukin-3 (Invitrogen, Paisley, UK) in 0.5% penicillin/strep-
tomycin antibiotics. Cells were incubated at 37 °C in 5% CO2. 
Total viable cells were counted using the trypan exclusion 
assay. For the alkaline phosphatase assay, ~2.5 × 105 progeni-
tor cells in 24-wells were transfected twice with the oligonucle-
otides at 100 nmol/l and the cells were harvested 72 hours 
later as described in the alkaline phosphatase assay kit (Cell 
Biolabs, San Diego, CA and Millipore, Billerica, MA). Equal 
protein load at 100 µg of protein was used for the assays and 
the reaction was measured after 1-hour incubation at 37 °C at 
405 nmol/l in an ELISA reader.
MicroRNA profiling. The detailed miRNA protocol is described 
previously.37 Adherent and nonadherent cells were added into 
a PCR tube and heat-treated at 95 °C for 5 minutes. Then the 
miRNAs were reverse transcribed into cDNAs by 460 miRNA-
specific stem-looped primers. Then these miRNA cDNAs were 
Figure 3  Functional analysis of miR-181a* and Nanog 3′ UTR region. (a, Top panel) a schematic of the base pairing between Nanog 
3′UTR and miR-181a*. (a, Bottom panel) an example of compensatory pairing as seen with let-7 microRNA (miRNA).11 The high comple-
mentarity-binding site at the 3′ region is indicated by the yellow highlights. (b, Top panel) in silico hybridization between miR-181a* and 
Nanog 3′ UTR region. RNAhybrid modeling demonstrating the most energy stable complementarity base pairing between miR-181a* and 
Nanog 3′ UTR mRNA. (b, Bottom panel) the loss of binding energy (mfe: –15.5 kcal/mol, relative to wild type) is caused by introducing two 
point mutations (cytidine (C) to adenosine (A), as shown by the blue color) therefore disrupting the binding properties of hsa-miR-181a*. 
(c) Reporter assay of Nanog 3′UTR and mutant Nanog 3′UTR in cells transfected with the mimic or inhibitor of miR-181a* oligonucleotides. 
Bar represents mean ± SD (n = 3). Statistical analysis, *P < 0.001.
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amplified by 18 cycles of PCR by 460-specific forward prim-
ers and a universal reverse primer. Finally, the cDNAs were 
split and individual miRNA was measured by TaqMan probe-
directed real-time PCR. All reactions were duplicated. The PCR 
was done as following by AB7900 with 384-well plates: first, 
95 °C for 10 minutes to activate the Taq polymerase. Then 40 
cycles of 95 °C for 15 seconds (for denaturation) and 60 °C for 
1 minute (for annealing and extension) were performed. Two 
replicates were performed for each sample. Two independent 
allogenic donor samples were used in the analysis. In order to 
obtain sufficient total RNAs, the adherent CD34+ progenitor 
cells were combined from the two donors.
RT-PCR and quantitative real-time RT-PCR. The miRNA-
181a* mimic and inhibitor were purchased from Dharmacon, 
Lafayette, CO. The oligonucleotides were transfected (at day 
0 and again at 24 hours) at 100 nmol/l into 1 × 105 adherent 
CD34+ stem cells using Nanofectamine reagent following the 
manufacturer’s recommendation (PAA, Pasching, Austria). 
Total RNA was harvested using the RNAqueous-Micro kit 
(Ambion, Paisley, UK) 72 hours post-transfection. The RNA 
was quantified using the Nanodrop 2000 micro-sample quan-
titator. Five hundred nanogram of total RNA from each sample 
was reverse transcribed using the One-Step RT-PCR kit from 
Qiagen (Hilden, Germany) following the manufacturer’s rec-
ommendation. Expression of human Nanog was measured 
semiquantitatively by PCR using primer pair from R&D Sys-
tems (Minneapolis, MN) after 32 cycles at 94 °C for 45 sec-
onds. 55 °C for 45 seconds and 72 °C for 45 seconds. GAPDH 
primers: Forward (5′GTGAAGGTCGGAGTCAACG3′) and 
Reverse (5′GGTGAAGACGCCAGTGGACTC3′) was used as 
a loading control after 30 cycles at 94 °C for 45 seconds. 60 
°C for 45 seconds and 72 °C for 1 minute. The samples were 
separated on agarose gel and analyzed using UVP Geldoc 
system (UVP, Upland, CA). Four sets of band intensity across 
three independent experiments were used for semiquantita-
tive analysis. For the quantitative real-time RT-PCR, 500 ng 
of total extracted RNA (as described above) was processed 
for elimination of genomic DNA followed by reverse transcrip-
tion using the QuantiTect Reverse Transcription kit from Qia-
gen. The first strand cDNA synthesis was then amplified for 
quantitative analysis of human Nanog (NM_024865) and the 
reference gene, human gluceraldehyde-3-phosphate-dehy-
drogenase (GAPDH) (NM_002046) using QuantiFast SYBR 
Green PCR Kit from Qiagen. Amplification was performed 
using Applied Biosystems 7900HT FAST-Real-Time System 
with 40 cycle conditions at 95 °C–15 seconds and 60 °C–45 
seconds with a total volume of 25 µl per sample. Amplified 
products were then analysed using Applied Biosystems RQ 
Manager 1.2.1. Four independent experiments were ampli-
fied in triplicates for quantitative analysis. Student t-test scor-
ing was performed at 99% confidence intervals.
Bioinformatic analysis. Sequence annotations and data were 
downloaded from version hg18 of the UCSC table browser’s Ref-
Seq Genes track.38 The genomic loci Nanog, STAT3, Hic1, Sox2, 
HoxB4, and POU5F1 (Oct4) were scanned for putative target 
sites for miR-181a* (5′-ACCAUCGACCGUUGAUUGUACC-3′). 
More specifically, the genes’ annotated 3′ UTR sequences were 
scanned for (i) seed sites with perfect reverse-complementa-
rity to the oligonucleotide’s seed sequence (nucleotides 2–7 
from the 5′ end) and (ii) sites with strong overall complimen-
tarily to the oligonucleotide. Such sites could be target sites for 
miRNA-like translational suppression and mRNA degradation, 
and small interfering RNA-like mRNA cleavage. The former 
scan used a custom python script, whereas the second scan 
used RNAhybrid39 with default parameter settings to evaluate 
potential hybridization between the oligo and target sequence. 
None of the five genes’ 3′ UTRs contained miRNA-like seed 
sites for the oligonucleotide. Of the sites that formed the most 
stable interactions with the oligonucleotide, the Nanog site was 
the most stable site that contained paired bases at the putative 
AGO2 cleavage site. The AGO2 cleavage site would presum-
ably be between nucleotides 10 and 11 from the 5′ end.40
Nanog 3´ UTR construct, cloning, and dual-luciferase 
reporter assay. Nanog 3´ UTR was amplified from HeLa 
genomic DNA by nested PCR using two different forward 
primers and a single reverse primer (primers are listed 
below). For both PCRs, 50 µl sample volumes were pre-
pared using 0.3 µmol/l each of Forward and Reverse prim-
ers, 1× Accuprime Pfx Reaction Mix (Invitrogen), and 1.0 
unit of Accuprime Pfx DNA Polymerase (Invitrogen). One 
hundred nanogram of genomic DNA and 0.5 µl of PCR 
product were used as templates in the first and the second 
PCR, respectively. The Forward 2 and the Reverse primers 
each contained two restriction enzyme cut sites; XhoI and 
SgfI for Forward 2 and NotI and EcoRI for Reverse. The 
Nanog 3´ UTR construct was cloned into the psiCHECK 2.2 
vector (Promega, Madison, WI), using the unique restriction 
enzyme cut sites for NotI and XhoI. Two point mutations were 
inserted in the Nanog 3´UTR target site of hsa-miR-181a* 
using two mutagenic primers and psiCHECK 2.2 with 
Nanog 3´ UTR insert as template. A 25.5 µl PCR sample 
volume was prepared using 10 ng of template, 0.5 µmol/l 
of each primer, 1× Reaction buffer (Agilent Technologies, 
Santa Clara, CA), dNTP mix (0.2 µmol/l each, Finnzymes), 
and 1.25 units of PfuTurbo DNA polymerase (Stratagene). 
Sequence of mutated hsa-miR-181a* target site (mutations 
in bold and underlined): GTGAAGTGGCGAGGTCTTGGC. 
List of primer sequences: Forward 1, AGCAACCAGAC-
CCAGAACATCCAG; Forward 2,GCGATCGCTCGAGAG-
ATGAGTGAAACTGATATTACTCAATTTCAGTCTGG;Rever
se,GAATTCGCGGCCGCATGTTTAAGCTGTATATTTACTC
ATTGAAACACTCGG; psiCHECK+, AGGACGCTCCAGAT-
GAAATG; Nanog seq, TCACTGCAAGCTCCGTCTCC; Rev 
psiCHECK, CAAACCCTAACCACCGCTTA; Nanog Mut Fr, 
GGCTGGAGTGAAGTGGCGAGGTCTTGGCTC; Nanog 
Mut Rev, GAGCCAAGACCTCGCCACTTCACTCCAGCC. 
For the reporter luciferase reporter assay, 100 nmol/l of 
miR181a* mimic or its inhibitor (Dharmacon) were trans-
fected into CD34 progenitor cells (2.5 × 105 cells/well) in a 
24-well plate for 24 hours. The Nanog 3′UTR wild-type or 
mutant with two point mutations was cloned downstream of 
the Renilla translational stop codon in psiCHECK-2 vector 
(Promega). 100 ng of the 3-UTR-Nanog (3-UTR-Nanog-psi-
CHECK-2) or its mutated variant was cotransfected into the 
cells pre-conditioned with miR181a* mimic or inhibitor for 
further 24 hours before harvesting. Empty (psiCHECK-2) 
vector was used for normalization and 3-UTR-Nanog alone 
was used as a control. Renilla and Firefly luciferase assay 
www.moleculartherapy.org/mtna
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was carried out using the Dual-Luciferase Reporter Assay 
System (Promega). Readings were measured the VICTOR 
plate reader (Waltham, MA) (Perkin-Elmer VICTOR).
Statistical analysis. Statistical analysis was performed using 
Prism 3.0 software. Results are shown as the means ± SD. 
Differences between groups were assessed using the two-
tailed Student t-test.
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